Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Bowel Diseases | 84 | 2024 | 2428 | 12.980 |
Why?
|
Crohn Disease | 72 | 2023 | 2304 | 9.310 |
Why?
|
Drug Monitoring | 34 | 2023 | 956 | 8.530 |
Why?
|
Gastrointestinal Agents | 36 | 2023 | 494 | 7.740 |
Why?
|
Colitis, Ulcerative | 49 | 2023 | 1911 | 5.330 |
Why?
|
Tumor Necrosis Factor-alpha | 36 | 2023 | 4424 | 4.410 |
Why?
|
Biological Products | 13 | 2023 | 860 | 3.060 |
Why?
|
Azathioprine | 8 | 2022 | 354 | 2.570 |
Why?
|
Colonoscopy | 14 | 2020 | 1367 | 2.210 |
Why?
|
Antibodies, Monoclonal | 29 | 2022 | 9274 | 1.960 |
Why?
|
Colitis | 9 | 2022 | 1170 | 1.880 |
Why?
|
Immunosuppressive Agents | 15 | 2022 | 4153 | 1.760 |
Why?
|
Remission Induction | 17 | 2023 | 2386 | 1.620 |
Why?
|
Practice Guidelines as Topic | 14 | 2021 | 7281 | 1.610 |
Why?
|
Immunologic Factors | 12 | 2023 | 1580 | 1.520 |
Why?
|
Capsule Endoscopy | 6 | 2021 | 125 | 1.290 |
Why?
|
Gastroenterology | 5 | 2021 | 538 | 1.120 |
Why?
|
Mesalamine | 9 | 2016 | 136 | 1.110 |
Why?
|
Anti-Inflammatory Agents | 7 | 2018 | 1790 | 1.090 |
Why?
|
Conflict of Interest | 6 | 2016 | 544 | 1.060 |
Why?
|
Guideline Adherence | 5 | 2020 | 2265 | 1.040 |
Why?
|
Serum | 3 | 2017 | 214 | 1.020 |
Why?
|
Evidence-Based Medicine | 7 | 2016 | 3610 | 1.000 |
Why?
|
Endoscopy, Gastrointestinal | 5 | 2023 | 868 | 0.940 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 14 | 2016 | 2282 | 0.900 |
Why?
|
Medical Records | 4 | 2017 | 1413 | 0.890 |
Why?
|
Bronchial Diseases | 2 | 2014 | 151 | 0.880 |
Why?
|
Standard of Care | 4 | 2022 | 564 | 0.870 |
Why?
|
Humans | 192 | 2024 | 744376 | 0.830 |
Why?
|
Pulmonary Medicine | 2 | 2014 | 213 | 0.820 |
Why?
|
Sickness Impact Profile | 2 | 2013 | 302 | 0.810 |
Why?
|
Documentation | 3 | 2017 | 871 | 0.800 |
Why?
|
Colectomy | 3 | 2015 | 680 | 0.770 |
Why?
|
Intestinal Fistula | 1 | 2021 | 140 | 0.730 |
Why?
|
Nephrology | 2 | 2014 | 263 | 0.730 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 319 | 0.720 |
Why?
|
Calculi | 1 | 2019 | 46 | 0.680 |
Why?
|
Fertilization in Vitro | 3 | 2016 | 1284 | 0.670 |
Why?
|
Triage | 2 | 2015 | 977 | 0.630 |
Why?
|
Hepatitis B Core Antigens | 1 | 2018 | 92 | 0.630 |
Why?
|
Hepatitis B Antibodies | 1 | 2018 | 159 | 0.610 |
Why?
|
Irritable Bowel Syndrome | 2 | 2013 | 445 | 0.600 |
Why?
|
Rectal Fistula | 1 | 2017 | 73 | 0.590 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 305 | 0.580 |
Why?
|
Hepatitis B virus | 2 | 2018 | 513 | 0.570 |
Why?
|
Coloring Agents | 1 | 2019 | 566 | 0.560 |
Why?
|
Drug Tolerance | 2 | 2018 | 376 | 0.560 |
Why?
|
Colonic Neoplasms | 5 | 2020 | 2542 | 0.560 |
Why?
|
Arthritis, Psoriatic | 1 | 2019 | 215 | 0.560 |
Why?
|
Diarrhea | 3 | 2017 | 1348 | 0.550 |
Why?
|
Immunocompromised Host | 2 | 2012 | 847 | 0.550 |
Why?
|
Light | 2 | 2020 | 1374 | 0.550 |
Why?
|
Virus Activation | 1 | 2018 | 319 | 0.550 |
Why?
|
Helicobacter pylori | 1 | 2019 | 383 | 0.550 |
Why?
|
Helicobacter Infections | 1 | 2019 | 387 | 0.540 |
Why?
|
Adult | 70 | 2023 | 214056 | 0.530 |
Why?
|
Cannabis | 1 | 2021 | 440 | 0.510 |
Why?
|
Disease Management | 6 | 2021 | 2460 | 0.500 |
Why?
|
Obstetric Labor Complications | 1 | 2017 | 238 | 0.500 |
Why?
|
Apyrase | 5 | 2020 | 364 | 0.500 |
Why?
|
Middle Aged | 61 | 2022 | 213388 | 0.490 |
Why?
|
Male | 83 | 2024 | 350118 | 0.480 |
Why?
|
Complementary Therapies | 2 | 2016 | 486 | 0.480 |
Why?
|
C-Reactive Protein | 7 | 2021 | 3778 | 0.470 |
Why?
|
Infertility | 3 | 2016 | 655 | 0.470 |
Why?
|
Therapeutic Irrigation | 2 | 2014 | 301 | 0.460 |
Why?
|
Female | 85 | 2024 | 380200 | 0.460 |
Why?
|
Herpesvirus 3, Human | 2 | 2012 | 204 | 0.460 |
Why?
|
Emergency Service, Hospital | 4 | 2018 | 7658 | 0.450 |
Why?
|
Pouchitis | 3 | 2022 | 62 | 0.450 |
Why?
|
Intestine, Small | 4 | 2013 | 1240 | 0.450 |
Why?
|
Mycobacterium marinum | 1 | 2012 | 26 | 0.430 |
Why?
|
Intestinal Obstruction | 2 | 2006 | 423 | 0.430 |
Why?
|
Treatment Failure | 5 | 2019 | 2618 | 0.420 |
Why?
|
Antirheumatic Agents | 2 | 2012 | 1338 | 0.420 |
Why?
|
Herpes Zoster | 2 | 2012 | 264 | 0.410 |
Why?
|
Coronary Angiography | 2 | 2014 | 4576 | 0.410 |
Why?
|
Barrett Esophagus | 1 | 2016 | 494 | 0.410 |
Why?
|
Skin Diseases, Bacterial | 1 | 2012 | 66 | 0.410 |
Why?
|
Treatment Outcome | 27 | 2022 | 63115 | 0.410 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 343 | 0.400 |
Why?
|
Chickenpox | 1 | 2012 | 131 | 0.390 |
Why?
|
Drug Evaluation | 1 | 2012 | 647 | 0.390 |
Why?
|
Cannabinoids | 1 | 2013 | 166 | 0.390 |
Why?
|
Cryptosporidium | 1 | 2011 | 45 | 0.390 |
Why?
|
Comparative Effectiveness Research | 3 | 2020 | 681 | 0.390 |
Why?
|
Th17 Cells | 5 | 2022 | 766 | 0.390 |
Why?
|
Drug Hypersensitivity | 2 | 2014 | 884 | 0.380 |
Why?
|
Cyclosporine | 2 | 2011 | 788 | 0.380 |
Why?
|
Cryptosporidiosis | 1 | 2011 | 60 | 0.380 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1070 | 0.380 |
Why?
|
Capsule Endoscopes | 2 | 2009 | 16 | 0.380 |
Why?
|
Arthritis, Rheumatoid | 2 | 2019 | 3712 | 0.370 |
Why?
|
Medication Adherence | 5 | 2015 | 2063 | 0.370 |
Why?
|
Tomography, X-Ray Computed | 5 | 2016 | 20130 | 0.360 |
Why?
|
Adrenal Cortex Hormones | 4 | 2014 | 1856 | 0.360 |
Why?
|
Delivery, Obstetric | 1 | 2017 | 906 | 0.350 |
Why?
|
Iatrogenic Disease | 1 | 2013 | 547 | 0.350 |
Why?
|
Osteoporosis | 1 | 2019 | 1579 | 0.350 |
Why?
|
Infertility, Female | 1 | 2016 | 788 | 0.350 |
Why?
|
Vaccines, Attenuated | 1 | 2011 | 342 | 0.350 |
Why?
|
Cellulitis | 1 | 2011 | 206 | 0.340 |
Why?
|
Colonic Polyps | 1 | 2014 | 542 | 0.340 |
Why?
|
Opportunistic Infections | 1 | 2012 | 389 | 0.340 |
Why?
|
Immunomodulation | 1 | 2013 | 541 | 0.340 |
Why?
|
Health Priorities | 1 | 2012 | 380 | 0.330 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3842 | 0.320 |
Why?
|
Tumor Necrosis Factors | 2 | 2019 | 109 | 0.320 |
Why?
|
Drug Substitution | 2 | 2021 | 281 | 0.320 |
Why?
|
Cesarean Section | 1 | 2017 | 1365 | 0.320 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 3922 | 0.320 |
Why?
|
Research Support as Topic | 1 | 2012 | 705 | 0.320 |
Why?
|
Potentilla | 1 | 2007 | 1 | 0.320 |
Why?
|
Retrospective Studies | 24 | 2019 | 77459 | 0.310 |
Why?
|
Infusions, Parenteral | 1 | 2008 | 419 | 0.310 |
Why?
|
Patient Care | 1 | 2013 | 640 | 0.310 |
Why?
|
Young Adult | 25 | 2023 | 56434 | 0.310 |
Why?
|
Congenital Abnormalities | 1 | 2013 | 707 | 0.310 |
Why?
|
Cytomegalovirus Infections | 1 | 2013 | 820 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10943 | 0.290 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 2006 | 60 | 0.280 |
Why?
|
Lichen Planus, Oral | 1 | 2007 | 56 | 0.280 |
Why?
|
Adenoma | 2 | 2014 | 2174 | 0.280 |
Why?
|
Colon | 5 | 2017 | 1772 | 0.280 |
Why?
|
Colorectal Neoplasms | 3 | 2014 | 6773 | 0.270 |
Why?
|
Hepatitis B | 1 | 2011 | 695 | 0.270 |
Why?
|
Private Practice | 2 | 2017 | 154 | 0.270 |
Why?
|
Antigens, CD | 4 | 2020 | 4026 | 0.270 |
Why?
|
Education, Medical | 1 | 2017 | 1722 | 0.260 |
Why?
|
Skin Diseases | 1 | 2014 | 1066 | 0.260 |
Why?
|
Clinical Protocols | 3 | 2009 | 1462 | 0.260 |
Why?
|
Severity of Illness Index | 12 | 2023 | 15535 | 0.260 |
Why?
|
Ambulatory Care | 2 | 2015 | 2708 | 0.260 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3873 | 0.250 |
Why?
|
Prospective Studies | 19 | 2023 | 53291 | 0.250 |
Why?
|
Prognosis | 15 | 2023 | 29060 | 0.250 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1831 | 0.240 |
Why?
|
Plant Extracts | 1 | 2007 | 471 | 0.240 |
Why?
|
Digestive System Surgical Procedures | 1 | 2009 | 576 | 0.240 |
Why?
|
Endoscopy | 4 | 2020 | 1787 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2022 | 9957 | 0.230 |
Why?
|
Infusions, Intravenous | 4 | 2014 | 2274 | 0.230 |
Why?
|
Delphi Technique | 3 | 2021 | 779 | 0.220 |
Why?
|
Mucous Membrane | 3 | 2023 | 673 | 0.220 |
Why?
|
Colonic Pouches | 3 | 2016 | 121 | 0.220 |
Why?
|
Hypersensitivity, Immediate | 1 | 2005 | 337 | 0.210 |
Why?
|
Autoimmune Diseases | 1 | 2014 | 2133 | 0.210 |
Why?
|
Consensus | 4 | 2021 | 2960 | 0.210 |
Why?
|
Ileitis | 1 | 2022 | 44 | 0.210 |
Why?
|
Cohort Studies | 12 | 2020 | 40558 | 0.200 |
Why?
|
Antibodies | 3 | 2023 | 2460 | 0.200 |
Why?
|
Physicians | 2 | 2017 | 4567 | 0.200 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15078 | 0.200 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1671 | 0.200 |
Why?
|
Patient Readmission | 1 | 2015 | 3116 | 0.200 |
Why?
|
Odds Ratio | 5 | 2020 | 9849 | 0.200 |
Why?
|
Hospitalization | 4 | 2018 | 10259 | 0.190 |
Why?
|
Probiotics | 3 | 2016 | 351 | 0.190 |
Why?
|
Adolescent | 14 | 2023 | 85784 | 0.190 |
Why?
|
Pregnancy Complications | 2 | 2013 | 2861 | 0.190 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2022 | 708 | 0.190 |
Why?
|
Research Design | 2 | 2015 | 5986 | 0.180 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 3086 | 0.180 |
Why?
|
Societies, Medical | 5 | 2021 | 3743 | 0.180 |
Why?
|
RNA, Antisense | 1 | 2020 | 138 | 0.180 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2020 | 370 | 0.180 |
Why?
|
Disclosure | 3 | 2015 | 736 | 0.170 |
Why?
|
Intestinal Mucosa | 5 | 2021 | 3037 | 0.170 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2019 | 300 | 0.170 |
Why?
|
Nitroimidazoles | 2 | 2010 | 106 | 0.170 |
Why?
|
Health Services Research | 2 | 2017 | 1836 | 0.170 |
Why?
|
Follow-Up Studies | 16 | 2018 | 39052 | 0.160 |
Why?
|
Tuberculosis | 1 | 2011 | 1912 | 0.160 |
Why?
|
Anticoagulants | 1 | 2014 | 4600 | 0.160 |
Why?
|
Wound Healing | 3 | 2021 | 2785 | 0.160 |
Why?
|
Recurrence | 6 | 2020 | 8340 | 0.160 |
Why?
|
Vaccination | 1 | 2011 | 3279 | 0.160 |
Why?
|
Diagnosis, Differential | 6 | 2013 | 12961 | 0.160 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 281 | 0.160 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 591 | 0.160 |
Why?
|
Sexually Transmitted Diseases | 1 | 2024 | 623 | 0.150 |
Why?
|
Focus Groups | 4 | 2021 | 1321 | 0.150 |
Why?
|
Aged, 80 and over | 11 | 2022 | 57776 | 0.150 |
Why?
|
Risk Factors | 15 | 2019 | 72295 | 0.150 |
Why?
|
Anti-Bacterial Agents | 3 | 2022 | 7182 | 0.150 |
Why?
|
Sensitivity and Specificity | 6 | 2021 | 14723 | 0.150 |
Why?
|
Moxibustion | 1 | 2016 | 8 | 0.150 |
Why?
|
Risk Assessment | 7 | 2019 | 23336 | 0.150 |
Why?
|
Drug Therapy, Combination | 4 | 2018 | 6489 | 0.150 |
Why?
|
Time Factors | 9 | 2016 | 40077 | 0.150 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1677 | 0.140 |
Why?
|
Trichuris | 1 | 2016 | 32 | 0.140 |
Why?
|
Cytokine Receptor Common beta Subunit | 1 | 2016 | 22 | 0.140 |
Why?
|
Enteric Nervous System | 2 | 2017 | 189 | 0.140 |
Why?
|
Hypnosis | 1 | 2016 | 82 | 0.140 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2759 | 0.140 |
Why?
|
Plant Preparations | 1 | 2016 | 94 | 0.140 |
Why?
|
Herpes Zoster Vaccine | 1 | 2016 | 47 | 0.130 |
Why?
|
Radiography | 3 | 2017 | 7023 | 0.130 |
Why?
|
Chi-Square Distribution | 2 | 2014 | 3508 | 0.130 |
Why?
|
Proctocolectomy, Restorative | 3 | 2016 | 189 | 0.130 |
Why?
|
Neurofibromatosis 1 | 1 | 2001 | 570 | 0.130 |
Why?
|
Aged | 17 | 2022 | 163284 | 0.130 |
Why?
|
Relaxation Therapy | 1 | 2016 | 178 | 0.130 |
Why?
|
Anastomosis, Surgical | 2 | 2016 | 987 | 0.130 |
Why?
|
Live Birth | 2 | 2016 | 512 | 0.130 |
Why?
|
Immunoglobulin Fab Fragments | 3 | 2011 | 482 | 0.130 |
Why?
|
Diagnosis-Related Groups | 1 | 2016 | 455 | 0.130 |
Why?
|
Ileostomy | 1 | 2015 | 119 | 0.130 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 840 | 0.120 |
Why?
|
Pregnancy | 6 | 2017 | 29144 | 0.120 |
Why?
|
Integrins | 1 | 2019 | 846 | 0.120 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 82 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.120 |
Why?
|
Government Regulation | 1 | 2019 | 522 | 0.120 |
Why?
|
Jews | 1 | 2016 | 385 | 0.120 |
Why?
|
Frameshift Mutation | 1 | 2016 | 399 | 0.120 |
Why?
|
Needs Assessment | 1 | 2020 | 1146 | 0.120 |
Why?
|
Boston | 3 | 2016 | 9312 | 0.120 |
Why?
|
Logistic Models | 3 | 2015 | 13409 | 0.120 |
Why?
|
Infection Control | 1 | 2021 | 965 | 0.120 |
Why?
|
Ileum | 1 | 2016 | 565 | 0.120 |
Why?
|
Integrin alpha4 | 1 | 2013 | 92 | 0.110 |
Why?
|
Follicle Stimulating Hormone | 1 | 2016 | 744 | 0.110 |
Why?
|
Mind-Body Therapies | 1 | 2016 | 247 | 0.110 |
Why?
|
Lymphoma | 2 | 2021 | 1877 | 0.110 |
Why?
|
ROC Curve | 2 | 2018 | 3527 | 0.110 |
Why?
|
Public Health Practice | 1 | 2015 | 218 | 0.110 |
Why?
|
Adenosine Triphosphatases | 1 | 2017 | 839 | 0.110 |
Why?
|
Yoga | 1 | 2016 | 253 | 0.110 |
Why?
|
Patient Compliance | 2 | 2014 | 2685 | 0.110 |
Why?
|
Salicylic Acid | 1 | 2013 | 56 | 0.110 |
Why?
|
Self Report | 5 | 2015 | 3557 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2016 | 4561 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 258 | 0.110 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 903 | 0.110 |
Why?
|
Child | 8 | 2023 | 77708 | 0.110 |
Why?
|
Secondary Prevention | 4 | 2013 | 1530 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4933 | 0.110 |
Why?
|
Autoantibodies | 1 | 2021 | 2036 | 0.110 |
Why?
|
Leukocytes, Mononuclear | 3 | 2016 | 1837 | 0.110 |
Why?
|
Acupuncture Therapy | 1 | 2016 | 464 | 0.100 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2014 | 339 | 0.100 |
Why?
|
Histocytochemistry | 1 | 2013 | 719 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1146 | 0.100 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 25041 | 0.100 |
Why?
|
Double-Balloon Enteroscopy | 1 | 2011 | 9 | 0.100 |
Why?
|
Chronic Disease | 3 | 2021 | 9145 | 0.100 |
Why?
|
Polyradiculopathy | 1 | 2011 | 23 | 0.100 |
Why?
|
5'-Nucleotidase | 1 | 2012 | 160 | 0.100 |
Why?
|
Hematocrit | 1 | 2013 | 636 | 0.100 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 349 | 0.100 |
Why?
|
DNA, Viral | 1 | 2018 | 2227 | 0.100 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 432 | 0.100 |
Why?
|
Polyethylene Glycols | 3 | 2011 | 1182 | 0.100 |
Why?
|
Lectins | 1 | 2013 | 513 | 0.100 |
Why?
|
Meningitis, Viral | 1 | 2011 | 50 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12244 | 0.100 |
Why?
|
Osteoarthritis, Hip | 1 | 2015 | 412 | 0.100 |
Why?
|
Purines | 1 | 2014 | 594 | 0.100 |
Why?
|
Chickenpox Vaccine | 1 | 2011 | 79 | 0.100 |
Why?
|
Tuberculin Test | 1 | 2011 | 214 | 0.090 |
Why?
|
Abdominal Pain | 1 | 2017 | 1064 | 0.090 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2011 | 66 | 0.090 |
Why?
|
Self Efficacy | 1 | 2014 | 616 | 0.090 |
Why?
|
Acyclovir | 1 | 2011 | 272 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2023 | 19905 | 0.090 |
Why?
|
Tissue Distribution | 1 | 2014 | 2327 | 0.090 |
Why?
|
Hematologic Diseases | 1 | 2014 | 498 | 0.090 |
Why?
|
Models, Organizational | 1 | 2014 | 574 | 0.090 |
Why?
|
Inflammation | 5 | 2014 | 10636 | 0.090 |
Why?
|
Steroids | 1 | 2015 | 930 | 0.090 |
Why?
|
Patient Admission | 1 | 2018 | 1380 | 0.090 |
Why?
|
Piperidines | 1 | 2018 | 1602 | 0.090 |
Why?
|
Mycobacterium | 1 | 2011 | 249 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2013 | 2987 | 0.090 |
Why?
|
Length of Stay | 2 | 2015 | 6311 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1316 | 0.090 |
Why?
|
Exercise Therapy | 1 | 2016 | 904 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 2958 | 0.080 |
Why?
|
Qualitative Research | 2 | 2015 | 2682 | 0.080 |
Why?
|
Infant, Low Birth Weight | 1 | 2013 | 850 | 0.080 |
Why?
|
Case-Control Studies | 6 | 2017 | 21747 | 0.080 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 187 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1343 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6539 | 0.080 |
Why?
|
Hypothalamic Hormones | 1 | 2008 | 147 | 0.080 |
Why?
|
Pituitary Hormones | 1 | 2008 | 183 | 0.070 |
Why?
|
Polysaccharides | 1 | 2014 | 1059 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2021 | 12025 | 0.070 |
Why?
|
Plants, Medicinal | 1 | 2007 | 167 | 0.070 |
Why?
|
Mice, Inbred NOD | 2 | 2022 | 1879 | 0.070 |
Why?
|
Acute Disease | 2 | 2009 | 7147 | 0.070 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2007 | 87 | 0.070 |
Why?
|
Immune Tolerance | 2 | 2014 | 2259 | 0.070 |
Why?
|
Heparin | 1 | 2014 | 1637 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2016 | 3296 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 2988 | 0.070 |
Why?
|
Melanins | 1 | 2008 | 289 | 0.070 |
Why?
|
Pyrimidines | 1 | 2018 | 2943 | 0.070 |
Why?
|
Forecasting | 2 | 2022 | 2951 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1438 | 0.070 |
Why?
|
Immunologic Memory | 1 | 2012 | 1348 | 0.070 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 2007 | 369 | 0.070 |
Why?
|
Phytotherapy | 1 | 2007 | 298 | 0.070 |
Why?
|
Postoperative Complications | 3 | 2015 | 15295 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1222 | 0.060 |
Why?
|
Abdomen | 1 | 2011 | 1118 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2016 | 3177 | 0.060 |
Why?
|
Comorbidity | 1 | 2019 | 10388 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4687 | 0.060 |
Why?
|
Intestinal Absorption | 1 | 2006 | 420 | 0.060 |
Why?
|
Antibiotic Prophylaxis | 1 | 2010 | 639 | 0.060 |
Why?
|
Premedication | 1 | 2005 | 258 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1343 | 0.060 |
Why?
|
Biopsy | 2 | 2013 | 6755 | 0.060 |
Why?
|
Interleukin-8 | 3 | 2016 | 690 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1887 | 0.060 |
Why?
|
Parkinson Disease | 1 | 2018 | 2775 | 0.060 |
Why?
|
Registries | 1 | 2019 | 8091 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1622 | 0.060 |
Why?
|
Placebo Effect | 1 | 2007 | 502 | 0.060 |
Why?
|
Psoriasis | 1 | 2011 | 902 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2887 | 0.060 |
Why?
|
Drug Resistance | 1 | 2009 | 1608 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 4386 | 0.060 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2575 | 0.060 |
Why?
|
Metronidazole | 1 | 2004 | 217 | 0.060 |
Why?
|
Phosphoglycerate Kinase | 1 | 2022 | 68 | 0.050 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2022 | 52 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 35424 | 0.050 |
Why?
|
Data Collection | 1 | 2012 | 3339 | 0.050 |
Why?
|
Placebos | 2 | 2018 | 1676 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6542 | 0.050 |
Why?
|
Benzene | 1 | 2022 | 100 | 0.050 |
Why?
|
Ciprofloxacin | 1 | 2004 | 315 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 18373 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12262 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8319 | 0.050 |
Why?
|
Video Recording | 1 | 2006 | 949 | 0.050 |
Why?
|
Immunity, Mucosal | 1 | 2004 | 490 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2789 | 0.050 |
Why?
|
Formularies as Topic | 1 | 2021 | 91 | 0.050 |
Why?
|
Budesonide | 1 | 2022 | 154 | 0.050 |
Why?
|
Chemoprevention | 1 | 2003 | 319 | 0.050 |
Why?
|
United States | 3 | 2019 | 69869 | 0.050 |
Why?
|
Bilirubin | 1 | 2022 | 425 | 0.050 |
Why?
|
Premature Birth | 1 | 2013 | 1721 | 0.050 |
Why?
|
Antibody Formation | 1 | 2005 | 1402 | 0.050 |
Why?
|
Carcinoma, Papillary | 1 | 2006 | 783 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3224 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11525 | 0.050 |
Why?
|
Pharmaceutical Services | 1 | 2021 | 140 | 0.040 |
Why?
|
Social Support | 1 | 2009 | 2118 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1683 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5984 | 0.040 |
Why?
|
Regression Analysis | 1 | 2009 | 6459 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2005 | 1463 | 0.040 |
Why?
|
Area Under Curve | 2 | 2014 | 1655 | 0.040 |
Why?
|
Interleukin-17 | 2 | 2015 | 901 | 0.040 |
Why?
|
Animals | 8 | 2022 | 168770 | 0.040 |
Why?
|
Health Personnel | 1 | 2012 | 3219 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12720 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3309 | 0.040 |
Why?
|
Anaphylaxis | 1 | 2005 | 746 | 0.040 |
Why?
|
Intestines | 3 | 2016 | 1924 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17445 | 0.040 |
Why?
|
Patient Selection | 1 | 2009 | 4216 | 0.040 |
Why?
|
Mice | 7 | 2022 | 81202 | 0.040 |
Why?
|
Dextran Sulfate | 1 | 2017 | 236 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2022 | 1200 | 0.040 |
Why?
|
Reference Standards | 1 | 2020 | 1025 | 0.040 |
Why?
|
Causality | 1 | 2023 | 1275 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2004 | 974 | 0.040 |
Why?
|
Health Care Surveys | 2 | 2014 | 2453 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2015 | 73 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15221 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1728 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1041 | 0.030 |
Why?
|
Referral and Consultation | 2 | 2020 | 3529 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1613 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3690 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.030 |
Why?
|
Antibodies, Fungal | 1 | 2014 | 32 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2018 | 811 | 0.030 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2014 | 91 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2024 | 2055 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3270 | 0.030 |
Why?
|
Porins | 1 | 2014 | 81 | 0.030 |
Why?
|
Salicylates | 1 | 2014 | 126 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2016 | 336 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2016 | 220 | 0.030 |
Why?
|
Motivation | 2 | 2014 | 1971 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2017 | 435 | 0.030 |
Why?
|
Infant | 2 | 2018 | 35134 | 0.030 |
Why?
|
Administration, Oral | 3 | 2006 | 3914 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5390 | 0.030 |
Why?
|
Life Style | 2 | 2015 | 3835 | 0.030 |
Why?
|
Child, Preschool | 2 | 2018 | 41005 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2014 | 5974 | 0.030 |
Why?
|
Cytoskeleton | 1 | 2018 | 1185 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 25628 | 0.030 |
Why?
|
Anemia, Sickle Cell | 1 | 2001 | 1020 | 0.030 |
Why?
|
Quality of Life | 2 | 2014 | 12803 | 0.030 |
Why?
|
Colorimetry | 1 | 2013 | 147 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2006 | 2282 | 0.030 |
Why?
|
Probability | 2 | 2009 | 2506 | 0.030 |
Why?
|
Serologic Tests | 1 | 2014 | 374 | 0.030 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2014 | 289 | 0.030 |
Why?
|
Pregnancy Rate | 1 | 2014 | 643 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2007 | 7914 | 0.020 |
Why?
|
Specialization | 1 | 2016 | 776 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 435 | 0.020 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2014 | 404 | 0.020 |
Why?
|
Gene Frequency | 1 | 2018 | 3587 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 950 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 874 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2576 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2016 | 1011 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1297 | 0.020 |
Why?
|
Decision Trees | 1 | 2011 | 506 | 0.020 |
Why?
|
Incidence | 2 | 2009 | 20950 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2021 | 3475 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1708 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 976 | 0.020 |
Why?
|
Trinitrobenzenesulfonic Acid | 1 | 2008 | 68 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1186 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2011 | 297 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16367 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2014 | 1470 | 0.020 |
Why?
|
Reference Values | 2 | 2006 | 4982 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2012 | 1880 | 0.020 |
Why?
|
Urocortins | 1 | 2007 | 19 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4296 | 0.020 |
Why?
|
Monocytes | 1 | 2016 | 2596 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2013 | 1157 | 0.020 |
Why?
|
Alleles | 1 | 2018 | 6933 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7323 | 0.020 |
Why?
|
Health Services Accessibility | 2 | 2014 | 5135 | 0.020 |
Why?
|
Postoperative Period | 1 | 2011 | 1842 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1254 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6194 | 0.020 |
Why?
|
Enema | 1 | 2006 | 141 | 0.020 |
Why?
|
Enterotoxins | 1 | 2007 | 368 | 0.020 |
Why?
|
Attitude to Health | 1 | 2014 | 2052 | 0.020 |
Why?
|
Genome, Human | 1 | 2018 | 4420 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2012 | 1381 | 0.020 |
Why?
|
Administration, Topical | 1 | 2006 | 690 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3921 | 0.010 |
Why?
|
Sex Distribution | 1 | 2009 | 2297 | 0.010 |
Why?
|
Population Surveillance | 1 | 2014 | 2616 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2012 | 880 | 0.010 |
Why?
|
Age Distribution | 1 | 2009 | 2902 | 0.010 |
Why?
|
Macrophages | 1 | 2018 | 5660 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2014 | 2752 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7730 | 0.010 |
Why?
|
Neuropeptides | 1 | 2008 | 942 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14561 | 0.010 |
Why?
|
Signal Transduction | 2 | 2016 | 23406 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2971 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1284 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10400 | 0.010 |
Why?
|
Mice, SCID | 1 | 2007 | 2717 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8386 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 2007 | 931 | 0.010 |
Why?
|
Europe | 1 | 2008 | 3339 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3749 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2016 | 19233 | 0.010 |
Why?
|
Primary Health Care | 1 | 2016 | 4557 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 21833 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 2383 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 2499 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10484 | 0.010 |
Why?
|
Pedigree | 1 | 2006 | 4642 | 0.010 |
Why?
|
Health Care Costs | 1 | 2011 | 3209 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9445 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9735 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 16000 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2007 | 13035 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 12073 | 0.010 |
Why?
|